HIV Treatment Cuts Threaten Black Communities: Access Crisis Looms

A quiet but potentially devastating shift is underway in HIV treatment access across the United States. As of March 2026, at least 18 states have already reduced or restricted access to AIDS Drug Assistance Programs (ADAP), raising serious concerns about the future of care for those living with HIV, particularly within Black communities. Advocates warn these changes could interrupt treatment for thousands and undermine national efforts to combat the epidemic.

These programs, funded through the federal Ryan White HIV/AIDS Program, are a critical lifeline for individuals living with HIV, helping them afford medications that can cost upwards of $60,000 annually for drugs like Biktarvy, currently the most widely prescribed HIV medication in the US. For approximately 300,000 Americans – roughly a quarter of the nation’s HIV-positive population – ADAP programs represent their last resort for accessing life-saving treatment. The changes are happening as enrollment in ADAP programs has surged roughly 30 percent in recent years, partly due to Americans losing Medicaid coverage after pandemic-era protections expired.

The Cost of Care and a Shrinking Safety Net

The core issue driving these restrictions is the escalating cost of HIV medications coupled with largely flat federal funding for the Ryan White program over the past decade. David J. Johns, Ph.D., CEO and executive director of the National Black Justice Collective (NBJC), explains the situation starkly: “The federal government has been investing in the same level of funding while the cost for drugs and care have increased. This is a policy decision that elected leaders are making. And Black communities disproportionately are paying for it with our lives.”

States implementing restrictions include Florida, Pennsylvania, Kansas, Delaware, Rhode Island, Arizona, Michigan, Nevada, Alaska and Oklahoma, with five additional states currently considering similar measures. These changes aren’t simply bureaucratic adjustments; they’re directly impacting access to medication. Johns notes that these changes are “making it harder for people to qualify for assistance to afford drugs that have increased significantly in cost.”

The timing of these cuts coincides with the expiration of enhanced Affordable Care Act tax credits at the end of 2025, which drove up average ACA premiums by roughly 26 percent between 2025 and 2026, further limiting affordable insurance options for many.

Disproportionate Impact on Black Communities

The consequences of these policy shifts will not be felt equally. Black Americans already bear a disproportionate burden of the HIV epidemic, representing more than 40 percent of recent HIV diagnoses despite comprising only 13 percent of the U.S. Population. This disparity is particularly pronounced among Black women, who account for over 50 percent of new diagnoses, and Black transgender women, who represent 46 percent of new HIV diagnoses.

Geography also plays a critical role. Many of the states enacting restrictions are located in the South, a region with consistently high HIV rates and a large concentration of Black residents. In the South, HIV rates among Black women are 14% higher than those of white women, according to Johns.

Black same-gender-loving men are also significantly affected, accounting for 35 percent of all new HIV diagnoses nationally. This intersection of race, sexual orientation, and gender identity creates a particularly vulnerable population facing increased barriers to care.

Beyond Treatment: Prevention and the National Goal

The crisis extends beyond treatment access. Despite the availability of preventative medications like PrEP (pre-exposure prophylaxis), which can dramatically reduce the risk of HIV transmission, Black Americans remain underrepresented among PrEP users. This underscores the necessitate for increased outreach and education to address systemic barriers to prevention.

For those already living with HIV, consistent medication is paramount to suppressing the virus and preventing transmission. Interruptions in treatment can lead to viral rebound and drug resistance, potentially limiting future treatment options and increasing the risk of spreading the virus. As Johns emphasizes, “Missing doses means the virus can come back…What has been working for you might not work at all in the future.”

These cuts also directly contradict the national goal, initially set by President Trump in 2019, to end the HIV epidemic by 2030. Johns points out that the current trajectory is moving the country in the opposite direction.

Economic and Systemic Costs

The ramifications of reduced access to HIV care extend beyond individual health outcomes. Interruptions in preventative care can lead to higher emergency healthcare costs, increased hospitalizations, and a greater strain on public health systems. Johns warns that “people are going to be paying more…And we are all going to be paying more in terms of the cost of lives lost.”

What Can Be Done?

Advocates are urging individuals and policymakers to take immediate action. Here’s how to get involved:

• Know Your Status: Organizations like the National Black Justice Collective offer resources, including free at-home HIV testing kits. Learn more at NBJC’s website.
• Maintain Treatment: If you lose coverage, do not stop your medication abruptly. Consult with a healthcare provider to explore alternative options.
• Connect with Local Resources: Local AIDS service organizations can provide emergency medication assistance, patient support, and connections to Ryan White providers.
• Advocate for Funding: Contact your elected officials and demand increased funding for the Ryan White program.
• Support Community Organizations: Donate to and volunteer with organizations like the Black AIDS Institute, the National Black Justice Collective, and TruEvolution, which are working to expand resources and combat stigma. Find out more about the Black AIDS Institute.

Johns stresses the urgency of the situation: “This is fixable. But it requires political will. And political will requires constituent pressure.” He concludes, “The math doesn’t math. In a country that has the resources to end the HIV epidemic, choosing not to fund treatment is a political decision.”